RWA Wealth Partners LLC Sells 96,601 Shares of Quanterix Co. (NASDAQ:QTRX)

RWA Wealth Partners LLC reduced its position in shares of Quanterix Co. (NASDAQ:QTRX) by 50.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 96,602 shares of the company’s stock after selling 96,601 shares during the quarter. RWA Wealth Partners LLC owned about 0.25% of Quanterix worth $1,027,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in shares of Quanterix during the fourth quarter worth approximately $66,000. Peapack Gladstone Financial Corp bought a new stake in shares of Quanterix during the 3rd quarter valued at $131,000. Levin Capital Strategies L.P. acquired a new position in shares of Quanterix in the 4th quarter valued at $159,000. Tallon Kerry Patrick bought a new position in shares of Quanterix in the 4th quarter worth $169,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Quanterix during the third quarter worth $170,000. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on QTRX shares. Scotiabank restated an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Canaccord Genuity Group decreased their price objective on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 18th.

Quanterix Price Performance

NASDAQ QTRX opened at $6.51 on Tuesday. Quanterix Co. has a one year low of $6.16 and a one year high of $23.86. The firm has a market cap of $252.43 million, a P/E ratio of -6.14 and a beta of 1.33. The stock’s 50-day moving average is $7.94 and its 200-day moving average is $10.59.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. Equities analysts anticipate that Quanterix Co. will post -0.98 EPS for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.